Protection of salvianolate against atherosclerosis via regulating the inflammation in rats

Meng, Chun; Zhuo, Xiaoqing; Xu, Guo-hong; Liu, Jianli

doi:10.1007/s11596-014-1331-z

Cited by 19 publications

(16 citation statements)

References 29 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using atherosclerosis rats challegened by HFD, salvianolate treatment dose-dependently (60, 120 and 240 mg/kg for 12 weeks, i.p.) alleviated the atherosclerotic process via decreasing the levels of proinflammatory cytokines (plasma interleukin-6 (IL-6) and C reactive protein (CRP)) and increasing the number of regulatory T cells (Tregs) (cluster of differentiation (CD)4+CD25+Foxp3+) [82]. Tregs is demonstrated to prevent the development of atherosclerosis by reducing IL-6 expression [106] and CRP production [107].…”

Section: Effects Of S Miltiorrhiza and Its Isolated Compounds On Thementioning

confidence: 99%

Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases

Wang

Liu

et al. 2017

CPD

193

125

View full text Add to dashboard Cite

Salvia miltiorrhiza Bunge, also known as Danshen in Chinese, has been widely used to treat cardiovascular diseases (CVD) in China and other Asia countries. Here, we summarize literatures of the historical traditional Chinese medicine (TCM) interpretation of the action of Salvia miltiorrhiza, its use in current clinical trials, its main phytochemical constituents and its pharmacological findings by consulting Pubmed, China Knowledge Resource Integrated, China Science and Technology Journal, and the Web of Science Databases. Since 2000, 39 clinical trials have been identified that used S. miltiorrhiza in TCM prescriptions alone or with other herbs for the treatment of patients with CVD. More than 200 individual compounds have been isolated and characterized from S. miltiorrhiza, which exhibited various pharmacological activities targeting different pathways for the treatment of CVD in various animal and cell models. The isolated compounds may provide new perspectives in alternative treatment regimes and reveal novel chemical scaffolds for the development of anti-CVD drugs. Meanwhile, there are also some rising concerns of the potential side effects and drug-drug interactions of this plant. The insights gained from this study will help us to better understanding of the actions of this herb for management of cardiovascular disorders. As an herb of red root, S. miltiorrhiza will act as a potential red light to prevent the development of CVD.

show abstract

Section: Effects Of S Miltiorrhiza and Its Isolated Compounds On Thementioning

confidence: 99%

Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases

Wang

Liu

et al. 2017

CPD

193

125

View full text Add to dashboard Cite

show abstract

“…Salvianolate can also inhibit reactive oxygen species (ROS) production [17] and improve microvascular flow by inhibiting oxidative stress and apoptosis [5]. In addition, salvianolate can reduce serum IL-6, CRP levels or myocardial ischemia reperfusion injury induced by PCI in atherosclerosis rats [3,18].…”

Section: Discussionmentioning

confidence: 99%

“…Salvianolate is a traditional Chinese medicine extracted from salvia. Previous studies have confirmed that salvianolate has multiple effects including anti-inflammation [3], anti-platelet [4] and coronary microcirculation improvement [5], which could be a good candidate to improve PCI related myocardial injury or myocardial infarction. Till now, there has been no clinical data about whether salvianolate can reduce incidence or severity of PCI-related myocardial injury or myocardial infarction in non-STsegment elevation acute coronary syndrome (NSTE-ACS) patients undergoing elective PCI.…”

Section: Introductionmentioning

confidence: 90%

Protective Effects of Salvianolate on Myocardial Injury or Myocardial Infarction after Elective Percutaneous Coronary Intervention in NSTE-ACS Patients: A Randomized Placebo-Controlled Trial

Sun

et al. 2020

Chin. J. Integr. Med.

View full text Add to dashboard Cite

Percutaneous coronary intervention (PCI) can cause myocardial injury or myocardial infarction. There is unmet need to reduce incidence or severity of PCI related myocardial injury or myocardial infarction. This study is to evaluate the protective effects of salvianolate on PCI related myocardial injury or myocardial infarction after elective PCI in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients. Methods We enrolled patients with NSTE-ACS who underwent elective PCI. The patients were randomly assigned to the salvianolate group or the control group. The incidence and the severity of PCI related myocardial injury or myocardial infarction, in addition to major adverse cardiac events (MACEs) during one year follow-up after PCI were studied between the two groups. We also performed a multivariate logistic regression analysis to determine the independent factors for PCI related myocardial injury or myocardial infarction after elective PCI. Results Compared with the control group, salvianolate treatment reduced the incidence of PCI related severe myocardial injury or myocardial infarction (11.7% vs 26.5%, p = 0.035). The rate of MACEs or all-cause death within one month or one year after the procedure was not significantly different between the two groups. Conclusions Periprocedural treatment with salvianolate reduces the incidence of PCI related severe myocardial injury or myocardial infarction, although it does not influence clinical prognosis.

show abstract

“…The syndrome differentiation in TCM of salvianolate injection is blood stasis syndrome, usually occurring in CHD, arrhythmia and congestive heart failure. Pharmacological studies indicated that salvianolate injection could protect cardiomyocytes via reducing the levels of proinflammatory cytokines and inhibiting reactive oxygen species production [ 11 , 12 ]. A systematic review made by Zhang [ 13 ] in 2016 showed that the combined use of salvianolate injection and western medicine improved both the total effective rate and the electrocardiogram effective rate.…”

Section: Introductionmentioning

confidence: 99%

Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease

Dong

Guan

et al. 2018

Chin Med

View full text Add to dashboard Cite

BackgroundComplicated with the impact of aging population and urbanization, coronary heart disease (CHD) incurs more and more disease burdens in China. Salvianolate injection is a Chinese patent drug widely used for treating CHD in China. A series of studies have verified the efficacy of salvianolate injection , but the high drug cost has raised concerns. It is, therefore, important to conduct cost-consequence analysis to demonstrate whether salvianolate injection is associated with outcome improvement and cost containment. The aim of this study was to retrospectively evaluate the cost-consequence of salvianolate injection for the treatment of coronary heart disease by combining salvianolate injection with conventional treatment from a societal perspective.MethodsWe retrospectively studied hospitalized patients with CHD from August 2011 to December 2015 by using electronic medical record database. Patients who received salvianolate injection combined with conventional treatment were selected as exposed group, while those who received conventional treatment alone were selected as unexposed group. Propensity score matching (PSM) analysis was used to balance the characteristics of patients. After PSM, we evaluated hospital stay, total nitrates dosage, total medical costs, and subcategories costs. Patients with chronic ischemic heart disease were analyzed as a highly selected subcohort.ResultsFor the overall group, hospital stay was significantly decreased by 2.9 days (P < 0.05) and total nitrates dosage was significantly decreased by 172.4 mg (P < 0.05) in exposed group; cost savings of pharmacy cost, examination cost, laboratory cost, operation cost and treatment was observed as significant (at P < 0.05); and the additional expenditure of Chinese patent drug (1174.9 CNY) was less than the saving of total medical costs (2636.4 CNY). For chronic ischemic heart disease subcohort, compared with unexposed group, significant decreases were also found in hospital stay and total nitrates dosage (P < 0.05); cost savings were significant (P < 0.05) for exposed group in terms of total medical costs (4339.5 CNY) and subcategories costs (including pharmacy cost, examination cost, operation cost and treatment cost); and the additional expenditure of Chinese patent drug (1189.3 CNY) was less than the saving of total medical costs.ConclusionCompared with conventional treatment for the treatment of CHD, combination of salvianolate injection and conventional treatment was associated with a reduction in hospital stay and total nitrates dosage. The acquisition cost of Chinese patent drug (including salvianolate injection) was offset by a higher reduction in total medical costs, especially for chronic ischemic heart disease.Electronic supplementary materialThe online version of this article (10.1186/s13020-018-0185-x) contains supplementary material, which is available to authorized users.

show abstract

Protection of salvianolate against atherosclerosis via regulating the inflammation in rats

Cited by 19 publications

References 29 publications

Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases

Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases

Protective Effects of Salvianolate on Myocardial Injury or Myocardial Infarction after Elective Percutaneous Coronary Intervention in NSTE-ACS Patients: A Randomized Placebo-Controlled Trial

Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease

Contact Info

Product

Resources

About